AASLD 2018: hepatitis B guidance
International AASLD Current
Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance
Terrault NA, et al. Hepatology. 2018;67:1560–1599
DOI 10.1002/hep.29800 · Summary checked against the source: 2026-11
The AASLD 2018 guidance updated the 2016 AASLD hepatitis B guideline, adding tenofovir alafenamide (TAF) as a preferred drug. Pages are from Hepatology 2018;67(4). Use EASL 2025 for the newer European view; the main differences are summarised on the topic page.
At a glance
- ALT upper limit of normal for decisions: 35 U/L for men, 25 U/L for women. [p. 1569]
- Immune-active CHB = ALT ≥2 × ULN (or significant histological disease) plus HBV DNA >2,000 IU/mL (HBeAg-negative) or >20,000 IU/mL (HBeAg-positive). [p. 1584]
- Treat immune-active CHB to reduce liver complications. [Strong, Moderate · p. 1584]
- Preferred first-line drugs: PEG-IFN, entecavir, TDF, and TAF. Prefer TAF or entecavir with kidney or bone disease; TAF isn't for CrCl <15 mL/min or dialysis. [Strong, Low · p. 1584]
- Pregnancy: antiviral therapy in the third trimester if HBV DNA >200,000 IU/mL; HBIG and vaccine to the newborn within 12 hours. [p. 1567]
Preferred drugs
| Drug | Adult dose | Notes |
|---|---|---|
| PEG-IFN α-2a | 180 µg weekly for 1 year | Flu-like symptoms, mood change, cytopenia, autoimmunity. FBC monthly to 3-monthly, TSH 3-monthly |
| Entecavir | 0.5 mg daily (1 mg if lamivudine-exposed or decompensated) | Lactic acidosis rarely in decompensation |
| Tenofovir disoproxil (TDF) | 300 mg daily | Renal tubular dysfunction, reduced bone density |
| Tenofovir alafenamide (TAF) | 25 mg daily | Less renal and bone toxicity than TDF |
Adapted from AASLD 2018 Table 1 [p. 1562]
Who to screen
All pregnant women; people from countries with HBsAg prevalence ≥2%; people who inject drugs; men who have sex with men; anyone needing immunosuppression or chemotherapy; unexplained raised ALT or AST; donors; dialysis; HIV or HCV; household, needle-sharing and sexual contacts of HBsAg-positive people; health-care workers at risk; and others at risk. [p. 1564]
Clinical pearls
- AASLD thresholds are higher than EASL: ALT ≥2 × ULN, HBV DNA >20,000 (HBeAg+) or >2,000 (HBeAg−). EASL treats at DNA ≥2,000 with any ALT rise or significant fibrosis.
- "Normal" ALT is lower than many labs report: 35 U/L men, 25 U/L women.
- TAF and entecavir for kidney or bone disease.
Classes and levels of evidence
How AASLD 2018 grades its recommendations. Adapted from AASLD 2018 GRADE [p. 1583]. Hover over any class or level cited on this page to see what it means.
| Strength | Meaning | Wording used |
|---|---|---|
| Strong | Most informed patients would choose this; benefits clearly outweigh harms | |
| Conditional (weak) | The balance is closer or uncertain; many informed patients would choose differently |
| Level | Meaning |
|---|---|
| High quality | Further research very unlikely to change confidence in the estimate |
| Moderate quality | Further research may change confidence in the estimate |
| Low quality | Further research likely to change the estimate |
| Very low quality | Any estimate of effect is very uncertain |
The guideline rates the quality (certainty) of the evidence as high, moderate, low or very low, and each recommendation as strong or conditional (weak). A strong recommendation means most informed patients would choose the intervention; a conditional one means many would not.